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downregulating Tbx21.
Immunity
ArticleTranscription Factor Foxo1 Is a Negative Regulator
of Natural Killer Cell Maturation and Function
Youcai Deng,1,2,3,10 Yann Kerdiles,4,10 Jianhong Chu,3,10 Shunzong Yuan,3,5,10 Youwei Wang,3 Xilin Chen,3,5
Hsiaoyin Mao,3 Lingling Zhang,3 Jianying Zhang,6 Tiffany Hughes,3 Yafei Deng,2 Qi Zhang,2 Fangjie Wang,2
Xianghong Zou,3 Chang-Gong Liu,7 Aharon G. Freud,3 Xiaohui Li,2,11 Michael A. Caligiuri,1,3,8,11,* Eric Vivier,4,9,11
and Jianhua Yu1,3,8,11,*
1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
2Institute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing 400038, China
3The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
4Centre d’Immunologie de Marseille-Luminy, Aix-Marseille University UM2, Inserm U1104, CNRS UMR7280, Marseille 13288, France
5Department of Lymphoma, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
6Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
7Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8The James Cancer Hospital, The Ohio State University, Columbus, OH 43210, USA
9Service d’Immunologie, Assistance Publique - Hoˆpitaux de Marseille, Marseille 13385, France
10Co-first author
11Co-senior author
*Correspondence: michael.caligiuri@osumc.edu (M.A.C.), jianhua.yu@osumc.edu (J.Y.)
http://dx.doi.org/10.1016/j.immuni.2015.02.006SUMMARY
Little is known about the role of negative regulators in
controlling natural killer (NK) cell development and
effector functions. Foxo1 is a multifunctional tran-
scription factor of the forkhead family. Using amouse
model of conditional deletion in NK cells, we found
that Foxo1 negatively controlled NK cell differentia-
tion and function. Immature NK cells expressed
abundant Foxo1 and little Tbx21 relative to mature
NK cells, but these two transcription factors reversed
their expression as NK cells proceeded through
development. Foxo1 promoted NK cell homing to
lymph nodes by upregulating CD62L expression
and inhibited late-stage maturation and effector
functions by repressing Tbx21 expression. Loss of
Foxo1 rescued the defect in late-stage NK cell matu-
ration in heterozygous Tbx21+/ mice. Collectively,
our data reveal a regulatory pathway by which the
negative regulator Foxo1 and the positive regulator
Tbx21 play opposing roles in controlling NK cell
development and effector functions.
INTRODUCTION
Natural killer (NK) cells provide early surveillance against malig-
nant transformation and viral clearance (Di Santo, 2006; Vivier
et al., 2011). The capacity of NK cells to directly lyse target
cells is determined by the balance of activating and inhibitory
receptors (Lanier, 2005). Another mechanism by which NK cells
eliminate their target cells is through secretion of cytokines, such
as the pro-inflammatory cytokine interferon-g (IFN-g), whichparticipate in shaping the adaptive immune response (Vivier
et al., 2012).
Murine NK cells develop in the bone marrow from common
lymphoid progenitor cells through three continuous stages
defined as CD122+NK1.1DX5 precursor NK (pNK) cells,
CD122+NK1.1+DX5 immature NK (iNK) cells, and CD122+
NK1.1+DX5+ mature NK (mNK) cells, respectively (Colucci et al.,
2003; Ramirez and Kee, 2010). After acquisition of NK1.1 surface
expression, murine NK cells can be further classified into three
stages based on surface expression of CD11b and CD27:
CD11bCD27+, CD11b+CD27+, and CD11b+CD27 (Chiossone
et al., 2009; Hayakawa and Smyth, 2006; Huntington et al.,
2013;Narni-Mancinelli et al., 2011).NKcell development,matura-
tion, and effector functions depend on extrinsic and intrinsic
factors and are controlled by both positive and negative regula-
tors (Hesslein and Lanier, 2011). For extrinsic factors, we and
others previously showed that interleukin-15 (IL-15) plays a crit-
ical role in promoting NK cell development and effector functions
(Yu et al., 2013), while transforming growth factor-b (TGF-b)
has an important inhibitory role in this respect (Allan et al., 2010;
Marcoe et al., 2012; Yu et al., 2006). Intrinsic factors, including
the transcription factors Ikaros, Pu.1, Ets1, and VDUP-1, regulate
the early stages of NK development by promoting the generation
of pNK, while E4BP4, Id2, andMEF function during the iNK stage
to promote early NK maturation, and Gata-3, Tox, Tbx21,
Eomes, and Irf2 mainly modulate late-stage NK maturation
(Colucci et al., 2003; Hesslein and Lanier, 2011; Luevano et al.,
2012; Ramirez and Kee, 2010). The key role of Tbx21 in regulating
late-stage maturation of NK cells is supported by the fact that
the final stage CD11b+CD27 subpopulation is almost absent
in Tbx21-deficient (Tbx21/) mice (Townsend et al., 2004). In
addition, Tbx21/ mice are susceptible to challenge with
tumor cells, while infusion of wild-type (WT) NK cells restores
anti-tumor capacity in vivo (Werneck et al., 2008).
Until now, at least two fundamental questions regarding
NK cell development remain unaddressed. These include theImmunity 42, 457–470, March 17, 2015 ª2015 Elsevier Inc. 457
Li
n-
C
D
12
2+
(%
)
C
el
ln
um
be
r
Lin- CD122+
A
Ncr1iCre/+ Foxo1f/f Foxo3f/f
Ncr1iCre/+ Foxo1f/+ Foxo3f/f
Ncr1iCre/+ Foxo1f/f Foxo3f/+
Ncr1iCre/+ Foxo1f/+ Foxo3f/+
B cells T cells NK cells
Foxo1 (C29H4)
Foxo3 (75D8)
CD122
C
D
3/
C
D
19
Foxo3ΔNKFoxo1ΔNKWT Foxo1,3ΔNK
BM lymphocytesB
C
Spleen
CD3e
N
Kp
46
0.62 0.320.28 0.65pLN
Live CD19- cells
6.8 9.87.6 6.9
Foxo3ΔNKFoxo1ΔNKWT Foxo1,3ΔNK
9.0 6.17.2 4.7liver
C
el
ln
um
be
r
****
C
el
ln
um
be
r
C
el
ln
um
be
r
C
D
11
b-
C
D
27
+
C
D
11
b+
C
D
27
+
C
D
11
b+
C
D
27
-
CD62L
C
D
62
L-
(%
)
****
****
*
Foxo3ΔNK
Foxo1ΔNK
WT
Foxo1,3ΔNK
****
****
****
***
D
C
D
62
L-
(%
)
****
***
**
****
*
****
****
***
**
Total NK cells
Spleen pLN BM
Spleen
3.13.48 2.63 3.74
1.61 4.28
93.4
2.26 7.83
88.8
1.52 4.03
93.6
2.46 5.19
91.5
NK1.1
N
Kp
46
Figure 1. Foxo Transcription Factor Deficiency Impairs NK Cell Homing
(A) Intracellular flow cytometric analysis of Foxo1 and Foxo3 expression in splenic B cells (CD3CD19+), T cells (CD3+NK1.1), and NK cells
(CD19CD3NK1.1+NKp46+) from mice of the indicated genotypes.
(legend continued on next page)
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nature of the signaling pathway upstream of Tbx21 that controls
late-stage NK cell maturation and function and also whether
any intrinsic checkpoint factors negatively regulate NK cell
development. The latter question is important because negative
regulators or checkpoints are undoubtedly involved in NK cell
development or maturation, whereas all aforementioned tran-
scription factors that have been identified as participating in
this process are positive regulators. Foxos are transcription
factors whose expression is associated with the generation of
common lymphoid progenitors and the regulation of T cell and
B cell development and function (Chow et al., 2013; Hedrick
et al., 2012; Hess Michelini et al., 2013; Kim et al., 2013; Ouyang
et al., 2012; Staron et al., 2014; Togher et al., 2015). Some of
these elegant studies also demonstrate that Foxo1 and Foxo3
regulate their target genes in a highly cell- and context-specific
mechanism. This underscores the need for exploring Foxo’s
unique role in NK cell development and function. Here we
show that Foxo1, and/or to a lesser extent Foxo3, control NK
cell homing, maturation, and anti-tumor activity. In addition, we
demonstrate that the inhibitory role of Foxo1 on NK cell matura-
tion depends on its repressive activity on Tbx21 expression.
These findings highlight the importance of negative regulatory
checkpoints on NK cell development and activity and reveal
novel opportunities for manipulating NK cell activity.
RESULTS
Foxo Transcription Factors Control NK Cell Homing
Intrinsic negative regulators of NK cell development have gener-
ally not been well described. Phosphorylated Akt was reported
to inactivate Foxo transcription factors by inducing their exit
from the nucleus (Calnan and Brunet, 2008). While the Foxo
family of transcription factors include four members—Foxo1,
3, 4, and 6—extensive comparative analysis of gene-expression
databases revealed that NK cells express Foxo1, and to a lesser
extent Foxo3, but have no apparent expression of Foxo4 or
Foxo6 (data not shown). To determine their role in NK cell
biology, we crossed Ncr1iCre mice (Narni-Mancinelli et al.,
2011) with mice carrying floxed Foxo1 alleles (Foxo1fl/fl) as well
as floxed Foxo3 alleles (Foxo3fl/fl) to generate three NK cell-
specific conditional knockout models, referred as to Foxo1DNK,
Foxo3DNK, and Foxo1,3DNK, respectively. Whereas the expres-
sion of a single Foxo1 or Foxo3 allele was sufficient to maintain
expression of the proteins, intracellular flow cytometry con-
firmed the efficient and specific depletion of Foxo1 and/or
Foxo3 in CD3CD19NKp46+ cells when both floxed alleles
were present (Figure 1A). Initial flow cytometric analyses showed
that Foxo1 and/or Foxo3 deficiency does not alter the quantity
of LinCD122+ cells, nor the proportions of NK1.1+NKp46+ cells
in the bone marrow, thus excluding a role of Foxo1 and 3 in early
steps of NK cell development (Figure 1B). However, looking in
the periphery, we found that whereas NK cell proportions and
cell numbers were almost unchanged in spleen and liver, they(B) Flow cytometric analysis and enumeration of LinCD122+ bone marrow (BM)
(C) Frequency and enumeration of NK cells in the indicated organs (pLN, periphe
(D) Flow cytometry analysis of CD62L expression on CD19CD3 NK1.1+NK
subpopulations in the spleen. Each dot indicates one mouse (*p < 0.05, **p < 0.01
correction).were selectively decreased in the lymph nodes of Foxo1DNK
and Foxo1,3DNK mice, suggesting impaired homing properties
(Figure 1C). Foxo1 has been shown to control T cell trafficking
by regulating the expression of several homing receptors
including CD62L (Kerdiles et al., 2009). Consistent with these
data, we observed an increased proportion of CD62L NK cells
in lymphoid organs of Foxo1DNK but not Foxo3DNK mice, which
was mostly attributed to defective expression of CD62L on
immature CD11bCD27+ and, to a lesser extent, on CD11b+
CD27+ cells (Figure 1D). Importantly, we also found that this
phenotype was enhanced in Foxo1,3DNK when compared to
Foxo1DNK NK cells. These data demonstrated that Foxo1 tran-
scription factor regulates NK cell homing and further suggested
that both Foxo1 and Foxo3 control CD62L expression in devel-
oping NK cells, although Foxo1 is able to compensate for the
absence of Foxo3 (Figure 1D). Altogether, these data revealed
that Foxo transcription factors are dispensable for the early
steps of NK cell development but redundantly control NK cell
homing in the periphery, by regulating CD62L expression.
Foxo Transcription Factors Control NK Cell Maturation
We then examined the role of Foxo1 and Foxo3 in NK cell
maturation. In the spleen, we noticed an overall increase in the
frequency of the most mature CD11b+CD27 population in
Foxo1DNK, Foxo3DNK, and Foxo1,3DNK mice, which was asso-
ciated with a decrease in the CD11b+CD27+ population in
Foxo1DNK and Foxo1,3DNKmice (Figure 2A). Despite the reduced
representation of mature NK cells in these organs, we observed
a similar phenotype in the bone marrow and lymph nodes of
Foxo1DNK and Foxo1,3DNK mice. During the final stages of matu-
ration, NK cells sequentially acquire the expression of CD11b,
downregulate CD27 gene expression, and finally upregulate
the expression of CD43 (Chiossone et al., 2009; Hayakawa and
Smyth, 2006; Kim et al., 2002; Yokoyama et al., 2004). The above
results support the idea that Foxo transcription factors inhibit
the progression of CD11b+ NK cells across the latest maturation
stages. Accordingly, a specific analysis of CD11b+ NK cells re-
vealed a strong bias toward an overrepresentation of CD27
cells over CD27+ cells in the spleen and lymph nodes of
Foxo1DNK and Foxo1,3DNK mice (Figure 2B). In further support
of these results, CD43lo NK cells from Foxo1DNK and Foxo1,3DNK
mice displayed a robust downregulation of CD27 expression,
which was also apparent—though less important—in Foxo3DNK
mice (Figure 2C). Finally, we also observed that Foxo1 defi-
ciency, Foxo3 deficiency, and their double knockouts were
associated with increased proportions of KLRG1+ cells, whose
expression is generally associated with NK cell terminal differen-
tiation (Huntington et al., 2007; Narni-Mancinelli et al., 2011)
(Figure 2D).
To investigate whether Foxo1 deficiency affects the kinetics
of NK cell maturation, we separately transplanted an equal
number of bone marrow cells from CD45.2 Foxo1DNK mice or
Foxo1fl/fl control mice into lethally irradiated CD45.1 congeniccells.
ry lymph node).
p46+ cells from the indicated organs, as well as on the indicated NK cell
, ***p < 0.001, ****p < 0.0001; unpaired two-tailed Student’s t test with Welsh’s
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Figure 2. Foxo Transcription Factors Inhibit NK Cell Maturation
(A) Flow cytometric analysis and cumulative frequencies of NK cell subpopulations in the indicated organs, based on CD11b and CD27 expression
(pLN, periphery lymph nodes; BM, bone marrow).
(B) Calculated ratio between CD27 versus CD27+ cells among CD11b+ NK cells, based on data displayed in (A).
(C) Flow cytometric analysis and cumulative results of CD27 expression on CD43lo gated NK cells.
(D) Cumulative frequencies of KLRG1-expressing NK cells (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired two-tailed Student’s t test with Welsh’s
correction). See also Figure S1.
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mice. At 1, 2, and 3 weeks after transplantation, significantly
more CD11b+CD27 (mature) but fewer CD11+CD27+ (imma-
ture) NK cells were observed in the CD45.1 mice that received
bonemarrow cells from Foxo1DNK donors, as compared to those
infused with bone marrow cells from Foxo1fl/fl control donors
(Figure S1A). To determine whether this increase in mature
NK cells was stem cell intrinsic or microenvironment-dependent,
we created chimeras in Rag2/Il2rg/ mice (lacking T cells, B
cells and NK cells) by injecting bone marrow cells from CD45.1
WT and CD45.2 Foxo1DNK mice, mixed at a 1:1 ratio. As shown
by flow cytometry at 6 weeks post-transplantation, a greater
proportion of mature but fewer immature NK cells were derived
from CD45.2 Foxo1DNK bone marrow cells than from CD45.1
WT control cells (Figure S1B), suggesting that Foxo1-controlled
NK cell maturation is cell intrinsic.
Our above data thus revealed that, in addition to their role
in regulating NK cell homing, Foxo transcription factors also
repressmaturation of CD11b+CD27+ to CD11b+CD27NK cells.
Moreover, although the data indicate that both Foxo1 and
Foxo3 act redundantly, they strongly suggest that Foxo1 plays
a prominent role, possibly owing to its higher expression relative
to Foxo3 in NK cells as we aforementioned.
Foxo Protein Deficiency Enhances NK Cell Effector
Functions
Our finding that Foxo deficiency enhances NK cell maturation
motivated us to determine whether Foxo transcription factors
also repress effector functions. We first tested whether the
absence of Foxo1 and/or Foxo3 affect NK cell response to
cytokine stimulation. When stimulated with the highly potent
IL-12 and IL-18 cytokine combination or PMA and ionomycin,
we observed that the overall proportion of IFN-g-secreting cells
was not affected regardless of genotype. However, the absence
of Foxo factors was associated with an increased ‘‘per-cell’’
response to an IL-12 and IL-18 co-stimulation, as shown by
the increased IFN-g geometric (g) MFI of secreting cells (Fig-
ure 3A). In order to validate and gain further insight into this
effect, we turned to an in vitro system using the human NK cell
line, NKL, and a PINCO-Foxo1-GFP plasmid allowing us to
overexpress Foxo1 (Figure S2A). Cytokine induction of IFN-g
production was diminished in NKL cells overexpressing Foxo1
compared to those infected with an empty control vector (Fig-
ure 3B). The inhibitory effect of Foxo1 on cytokine activated
NK cells was discernible even in the presence of inhibitory
TGF-b signaling (Figure 3B). Conversely, we found that IFNG
mRNA transcript was increased when Foxo1 expression was
knocked down by short hairpin (sh) RNA in NKL cells (Figure 3C
and Figure S2B).
To further examine the negative regulatory effects of Foxo1 on
IFN-g gene expression, an inducible gene regulation approach
was undertaken. We infected NKL cells with a retrovirus
encoding a fusion protein consisting of Foxo1 and the estrogen
receptor ligand-binding domain (Foxo1-ER) (Amin and Schlissel,
2008), which becomes activated with the addition of the
estrogen analog 4-hydroxytamoxifen (4-OH-tamoxifen). After
confirming expression of Foxo1-ER in NKL cells with intracellular
staining (Figure S2C), we found that IFNG mRNA transcript
in cytokine-activated NKL cells was decreased at 3 and 6 hr
after the addition of 4-OH-tamoxifen (Figure 3D). Collectively,these data indicate that Foxo1 is a negative regulator of NK
cell effector function, in that its deficiency enhances NK cell
IFN-g production and its overexpression diminishes it.
We then tested the cytotoxic potential of Foxo-deficient
murine NK cells. Directly ex vivo, Foxo1-deficient NK cells had
increased cytotoxic potential against the prototypic Yac-1 target
cells (Figure 4A). Further, overexpression of Foxo1 in NKL cells
inhibits killing of K562 cells (Figure 4B). In this context, we postu-
lated that loss of Foxo1 in NK cells might enhance their ability
to prevent in vivo tumor progression. We utilized the B16F10
melanoma model of tumor metastasis (Werneck et al., 2008)
to investigate NK cell-mediated tumor surveillance in vivo by
enumerating the pulmonary tumor nodules 2 weeks after intra-
venous injection of B16F10 melanoma cells. We observed a
marked decrease in the number of melanoma nodules in the
lungs of Foxo1DNK mice compared with WT littermate controls
(Figure 4C). Altogether, these data demonstrate that Foxo tran-
scription factors restrain NK cell functions and anti-metastatic
activity in vivo.
Pro-inflammatory Cytokines and In Vivo Tumor
Challenge Inactivate Foxo1
We previously showed that pro-inflammatory cytokines can
inhibit negative regulators such as SHIP1 and SMADs in NK cells
(Trotta et al., 2005; Yu et al., 2006). IL-12 is an important cytokine
for regulating NK cell effector functions, such as IFN-g
production, and we and others also previously showed that
pro-inflammatory cytokines such as IL-15 and IL-2 are critical
factors for controlling NK cell development and function (Freud
et al., 2005; Yu et al., 2013). Phosphorylation of Foxo transcrip-
tion factors may interfere with their DNA-binding activity and
trigger their sequestration in the cytoplasm, thereby leading to
their inactivation (Calnan and Brunet, 2008). Thus, if Foxo tran-
scription factors are negative regulators of NK cell development
and function, it is possible that their phosphorylation status is
impacted by these pro-inflammatory cytokines. To assess this,
we incubated the human NK cell line NK-92 with IL-15, IL-2, or
IL-12, separately, for 5–120min andmeasured Foxo1 phosphor-
ylation. Compared to untreated samples, IL-15 induced phos-
phorylation of Foxo1 as early as 5 min, and the phosphorylation
remained elevated at subsequent time points. IL-2 and IL-12 also
induced phosphorylation of Foxo1 at all time points, whereas
the phosphorylation was highest at 120 min after treatment
(Figure 5A). We further confirmed these human data in mouse
spleen NK cells by intracellular staining for phospho-Foxo1Ser256
(Figure 5B). These observations therefore suggest that the pro-
inflammatory cytokines that activate NK cell effector function
and/or promote NK cell development can antagonize inhibitory
signaling through the phosphorylation and subsequent inactiva-
tion of Foxo1. These data are consistent with our previous find-
ings that pro-inflammatory cytokine signaling has a capacity to
antagonize inhibitory TGF-b signaling (Yu et al., 2006). We also
found that the ratio of phospho-Foxo1Ser256/Foxo1 was higher
in murine NK cells belonging to CD11b+CD27+ population than
CD11bCD27+ population, and was highest in CD11b+CD27
cells (Figure S3). We next determined the amount of Foxo1
phosphorylation after NK cells had been activated by tumor cells
in vivo. After challenged with B16F10 tumor cells, lung tissue NK
cells also showed increased Foxo1 phosphorylation, whereasImmunity 42, 457–470, March 17, 2015 ª2015 Elsevier Inc. 461
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Figure 3. Enhanced IFN-g Secretion following Cytokine Stimulation of Foxo-Deficient NK Cells
(A) Intracellular flow cytometric analysis of IFN-g production by splenic NK cells co-stimulated with IL-12 and IL-18, or PMA and ionomycin (Iono) for 4 hr in the
presence of Brefeldin A (Error bars, SD of experimental duplicates. One out of four experiments with a total of 6 to 10 mice per group).
(B) NKL cells transduced with PINCO-Foxo1 or PINCO empty vector were stimulated with the cytokines indicated for 18 hr for ELISA analysis of IFN-g.
(C) NKL cells expressing Foxo1 shRNA (shFoxo1) or empty vector control (EV) were treated with IL-12 for 12 hr and harvested for real-time RT-PCR to assess
IFNG mRNA.
(D) NKL cells expressing Foxo1-ER were treated with 4-OH-tamoxifen or ethanol carrier for indicated time points, followed by real-time RT-PCR analysis of IFNG
mRNA. Data shown in (B)–(D) are representative of at least two independent experiments, and error bars represent SD. *p < 0.05 and **p < 0.01 (unpaired
two-tailed Student’s t test). See also Figure S2.the amount of total Foxo1 remained unchanged (Figure 5C). Our
data therefore suggest that together with their inhibitory role in
effector functions, Foxo1 transcription factor inactivation upon
NK cell stimulation is required for their ‘‘full-blown’’ activation.
Furthermore, Foxo1’s regulation of activity might act as an
important negative checkpoint in controlling NK activation.
Differential Mechanisms of Foxo1 Suppressing Tbx21
Expression in Human and Mouse NK Cells
Foxo1 regulates NK cell development and effector function in a
manner which is opposite to that reported for Tbx21 (Gordon462 Immunity 42, 457–470, March 17, 2015 ª2015 Elsevier Inc.et al., 2012; Townsend et al., 2004), but both control NK cell
maturation at the late-stage checkpoint. To investigate whether
Foxo1 regulates Tbx21 expression or vice versa during NK cell
maturation, the temporal and spatial expression of Foxo1 and
Tbx21was assessed during NK cell maturation across the devel-
opmental stages defined by CD11b and CD27 surface expres-
sion. Both intracellular flow cytometry and real-time reverse
transcriptase (RT)-PCR demonstrated higher Foxo1 expres-
sion in CD11bCD27+ NK cell subpopulation compared with
CD11b+CD27+ and CD11b+CD27 subpopulations (Figure 6A),
whereas Tbx21 had the opposite expression pattern (Figure 6B).
05
10
15
20
25
30
10 5 1
Sp
ec
ifi
c
ce
ll
ly
si
s
(%
)
**
*
WT mouse NK cells
Foxo1ΔNK mouse NK cells
0
10
20
30
40
50
60
70
40 20 10
Sp
ec
ifi
c
ce
ll
ly
si
s
(%
)
NKL-PINCO
NKL-PINCO-Foxo1
**
*
A B
WT Foxo1Δ
*
0
50
100
150
200
250
Tu
m
or
N
od
ul
es
(N
o.
)
CYac-1 K562
Figure 4. Loss of Foxo1 Enhances Cytotoxic and Anti-metastatic Potential of NK Cells
(A) Assessment of natural cytotoxicity of FACS-sorted splenic NK cells against Yac-1 target cells using standard 51Cr-release assay (Error bars, S.D; n = 6; *p <
0.05 and **p < 0.01; unpaired two-tailed Student’s t test).
(B) NKL cells transduced with PINCO-Foxo1 or PINCO empty vector were used for a standard 51Cr-release assay to determine cytotoxicity against target K562
cells (representative of at least two independent experiments, and error bars represent SD. *p < 0.05 and **p < 0.01; unpaired two-tailed Student’s t test).
(C) Representative and summarized data of lung nodules from 8- to 12-week-old WT and Foxo1DNK mice 2 weeks after intravenous (i.v.) injection of 0.25 3 106
B16F10 melanoma cells. Each symbol represents an individual mouse, and the same symbols from the two groups indicate littermate pairs. Horizontal lines
represent means. *p < 0.05; generalized linear models; n = 7 to 10 for each genotype. See also Figure S2.Building on this inverse correlation between Foxo1 and Tbx21
expression, we next askedwhether Tbx21 regulated Foxo1 gene
expression. Real-time RT-PCR indicated that Foxo1 mRNA
expression was unchanged between NK cells isolated from
Tbx21/ mice and those isolated from their WT littermate
control mice (data not shown), arguing against a role of Tbx21
in the regulation of Foxo1 expression at the transcriptional level.
We then explored whether Foxo1 regulated Tbx21 expression. In
NK cells isolated from Foxo1DNK and control mice, we assessed
both Tbx21 mRNA and protein expression by real-time RT-PCR
and intracellular flow cytometry, respectively. Tbx21 mRNA and
protein expression were both increased in total NK cells isolated
from Foxo1DNK mice compared to those isolated from control
mice (Figures 6C and 6D). Considering that loss of Foxo1
enhanced late-stage NK cell maturation, we then used intracel-
lular flow cytometry to compare Tbx21 protein expression in
NK cell developmental stages isolated from Foxo1DNK and
control mice. We found that Tbx21 expression was elevated in
CD11b+CD27+ and CD11b+CD27 NK cells from Foxo1DNK
mice compared to those from control mice (Figure 6E). These
data suggest that the downregulation of Foxo1 triggers the
elevated Tbx21 expression during late stage maturation of NK
cell development.
We next tested these data in human NK cells. Addition of
4-OH-tamoxifen to induce Foxo1 activity in NKL cells expressing
Foxo1-ER, suppressed TBX21 mRNA expression at the 6 hr
time point (Figure 6F), while knockdown of Foxo1 augmented
TBX21 mRNA expression (Figure 6G).
Becausewe found that Foxo1 also inhibited TBX21 expression
in human NK cells (Figure 6F, G), we first asked whether Foxo1
binds to the TBX21 promoter in the human NKL cell line, which
possesses a potential forkhead-binding site of TTGTTTT
at 1,187 to 1,181 bp relative to the transcription start site.
Our chromatin immunoprecipitation (ChIP) assay revealed
that the chromatin fragments containing the potential fork-head-binding site from the human TBX21 promoter were indeed
specifically immunoprecipitated by anti-Foxo1 antibody in NKL
cells (Figure 6H). We next performed ChIP assay in purified
murine NK cells to determine whether Foxo1 binds to the
three putative forkhead-binding sites previously described
(around 4,635 bp, 1,541 bp and 744 bp regions) (Rao
et al., 2012) at the proximal region, as well as another one at
the remote region (around 16.6 kb) on the Tbx21 promoter.
Consistent with the previous observation (Rao et al., 2012), we
did not find any direct binding activity of Foxo1 at these putative
forkhead-binding sites on the Tbx21 promoter in mouse NK cells
(data not shown). To further determine the mechanism, we also
performed a microarray analysis on highly purified primary
mouse NK cells from Foxo1DNK and control mice. We aimed to
find whether Foxo1 regulated other factors, such as previously
identified Tbx21 regulators, Tox and Ezh2 (Tong et al., 2014;
Yun et al., 2011), and thereby indirectly regulated Tbx21 expres-
sion. We failed to identify such a mechanism (data not shown).
A previous report indicates that about 83% of genes regulated
by Foxo1 do not contain any consensus forkhead-binding sites
in the promoter regions (Dong et al., 2008). Together with the
above negative data that we collected, we hypothesized that
Foxo1 is recruited to the Tbx21 promoter through a protein-
protein interaction and thereby regulated Tbx21 expression.
After working on several potential binding partners of Foxo1,
we started to test this hypothesis in murine cells by investigating
the interaction between Foxo1 and Sp1, a Foxo1 protein binding
partner previously identified in other cell types (Li et al., 2007).
Indeed we demonstrated such an interaction in murine spleno-
cytes (Figure 6I), which was further validated in murine NK cells
(Figure 6J). In humans, we previously identified six putative SP1
binding sites on the proximal TBX21 promoter spanning
from 160 to +110 bp relative to the transcription start site,
whichwere highly homologous among different mammalian spe-
cies (Yu et al., 2007).We also demonstrated the binding of SP1 toImmunity 42, 457–470, March 17, 2015 ª2015 Elsevier Inc. 463
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Figure 5. Pro-inflammatory Cytokines and
Tumor Challenges Induce Foxo1 Phosphor-
ylation
(A) NK-92 cells were stimulated with IL-15
(100 ng/ml), IL-2 (200 IU), or IL-12 (10 ng/ml). At
indicated time points, cells were harvested and
lysed, followed by immunoblot using a phosphor-
ylated (p)-Foxo1Ser256 antibody and a b-actin
antibody (internal control). Numbers under each
lane represent densitometric quantification of
p-Foxo1Ser256, after normalizing to b-actin. Data
shown are representative of two independent
experiments with similar results.
(B) Intracellular staining of p-Foxo1Ser256 in splenic
NK cells (gated on CD3NK1.1+) after being
stimulated with or without IL-15 (100 ng/ml), IL-2
(200 IU), or IL-12 (10 ng/ml) for 60 min.
(C) Intracellular staining of p-Foxo1Ser256 and total
Foxo1 in isolated lung tissue NK cells seven days
after i.v. injection with B16F10 melanoma cells.
Data in (B) and (C) are representative of three
different experiments with three mice per group
for each experiment. Error bars represent SD.
See also Figure S3.the TBX21 promoter in human cells (Yu et al., 2007), and recently
this was independently validated by a ChIP-seq from another
group (Araya et al., 2014). On the basis of these current and pre-
vious findings, we postulated that, if our above hypothesis was
correct, Foxo1 would be associated with the Tbx21 proximal
promoter at the Sp1 binding region. Our ChIP assay demon-
strated that in purified primary murine NK cells, Foxo1 was
indeed associated with the Tbx21 proximal promoter at the
putative Sp1 binding region (Figure 6K). Consistent with our pre-
vious findings in humans (Yu et al., 2007), Sp1 also showed bind-
ing activity at this region in murine NK cells (Figure 6K). All the
above evidences indicate that in murine NK cells Foxo1 sup-
presses Tbx21 expression through recruitment by Sp1 to the
Tbx21 proximal promoter region.
Foxo1 Requires Tbx21 to Exert Its Effect on NK
Cell Maturation
We undertook a genetic approach to further confirm our above
finding, showing that Foxo1 acts upstream of Tbx21 to nega-
tively regulate its expression. A previous study demonstrated464 Immunity 42, 457–470, March 17, 2015 ª2015 Elsevier Inc.that Tbx21/ mice almost completely
lose late-stage NK cell maturation (Town-
send et al., 2004). We therefore hypothe-
sized that Foxo1’s role in regulating NK
cell maturation required Tbx21 (Fig-
ure S4). To test this, we generated
Tbx21/ and Tbx21+/ Foxo1-deficient
mice, i.e., Foxo1DNKTbx21/ and
Foxo1DNKTbx21+/. Parallel analysis of
NK cells from these mice by flow cytome-
try indeed indicated that the function of
Foxo1 in NK cell maturation relied on the
existence of Tbx21. Specifically, when
both alleles of Tbx21 are WT, consistent
with the data shown in Figure 2,compared to control mice, loss of Foxo1 in Foxo1DNK mice was
associated with an increased proportion of CD11b+CD27 cells
(Figures 7A, left two columns, and 7C). However, when Tbx21
was absent in Foxo1DNKTbx21/ mice, compared to control
Tbx21/ mice, the loss of Foxo1 in Foxo1DNK Tbx21/ mice
had no further effect on late-stage NK cell maturation; i.e., ge-
netic deletion of Foxo1 failed to rescue the absence of late-stage
NK cell maturation observed in Tbx21/ mice (Figures 7A, right
two columns, and 7C). When only a single allele of Tbx21 was
present (i.e., Tbx21+/), the loss of Foxo1 in Foxo1DNK Tbx21+/
mice rescued the defect in NK cell maturation that occurred in
Tbx21+/ mice so that it was similar to that observed in WT con-
trol mice, but reduced compared tomaturation in Foxo1DNKmice
(Figures 7B and 7D). These data indicate that Foxo1 requires
Tbx21 to exert its negative effect on NK cell maturation.
DISCUSSION
The generation and maturation of NK cells are the result of an
elaborate series of cellular and molecular events that are often
associated with developmental regulators. Previously, a study
using systemic Tbx21/ mice identified Tbx21 as an intrinsic
positive regulator during a late stage of NK cell maturation
from relatively immature NK cells (Townsend et al., 2004).
Numerous other studies using similar approaches of systemic
knockout mice have identified other positive regulators of NK
cell development and effector functions (Hesslein and Lanier,
2011; Ramirez and Kee, 2010). Our focus has been on negative
regulators, or checkpoints, as they are undoubtedly involved in
this process yet are largely unknown. Understanding negative
regulatory factors in cell development is critical to define and
ultimately modulate these processes. We previously found that
TGF-b plays a role in negatively regulating NK cell function by
antagonizing positive signaling pathways (Yu et al., 2006) and,
subsequently, other groups found that TGF-b also acts as an
extrinsic negative regulator in NK cell development (Marcoe
et al., 2012). Of note, inhibition of TGF-b signaling with neutral-
izing antibodies and other approaches has been used to treat
cancer (Bouquet et al., 2011; Liu et al., 2012; Zwaagstra et al.,
2012).
In the current study, we utilizedNcr1iCremice (Narni-Mancinelli
et al., 2011) to generate NK cell conditional deletion of Foxo1
and/or Foxo3. Using this cell-specific approach, we found that
Foxo transcription factors act in multiple ways to regulate NK
cell homeostasis and function. Indeed, during the earliest steps
of NK cell maturation, Foxo transcription factors are involved in
the control of cell homing by regulating the expression of
CD62L (Martı´n-Fontecha et al., 2004), whereas they act as
negative regulators in the checkpoint controlling CD27 downre-
gulation and final maturation in CD11b+ NK cells. We also found
that Foxo1 negatively regulates NK cell effector functions.
Mechanistically, our data showed that Foxo1 inhibits Tbx21
expression in NK cells. In humans, this appears to occur via
direct binding to the TBX21 promoter, whereas in mice, Foxo1
is recruited by Sp1 to associate with the proximal promoter
region of Tbx21 where Sp1 binds. Consistent with this, Foxo1
and Tbx21 expression inversely correlate with each other from
immature NK cells to mature NK cells. Our findings support a
model in which the dynamic and inverse changes in Foxo1 and
Tbx21 expression control NK cell maturation and homeostasis
(Figure S5). During this process, Foxo1 is highly expressed while
Tbx21 is present in low amounts in immature NK cells. Along
with NK maturation, Foxo1 expression gradually decreases
and releases its control as a negative regulator of Tbx21, leading
to late-stage NK cell maturation. We believe that this negative
regulation of Tbx21 is important for tight control of NK cell
homeostasis. Loss of this balance might be associated with
diseases, as too many NK cells could promote autoimmune dis-
eases, while too few NK cells might result in earlier or more prob-
able malignant transformation.
In support of this proposed mechanism, our ChIP results
demonstrate that Foxo1 associates with a binding site (1,187
to 1,181) upstream of the transcription start site of TBX21 in
human NK cells. Consistent with previous work in T cells (Rao
et al., 2012), we were unable to show a direct binding of Foxo1
to the Tbx21 promoter in murine NK cells. A previous report
shows that about 83% of genes regulated by Foxo1 do not
contain any consensus forkhead-binding sites in the promoter
regions (Dong et al., 2008). This suggests that protein-proteininteractions might be responsible for Tbx21 suppression by
Foxo1 in murine cells. Consistent with this, our co-immunopre-
cipitation experiment using both murine splenocytes and NK
cells demonstrates that Foxo1 interacts with Sp1, and the
ChIP experiment shows that both Foxo1 and Sp1 are associated
with the proximal promoter region of Tbx21 at the Sp1 binding
region. We believed that we have unraveled one important
mechanism underlying inhibition of Tbx21 by Foxo1 in murine
NK cells although some other mechanisms might also exist.
Our current study is in accordance with previous data from
another group showing that Foxo1 interacts with Sp1 in another
cell type (Li et al., 2007) and is well corroborated by the data
from other groups and ours demonstrating that SP1 binds to
the proximal promoter region of TBX21 and regulates its expres-
sion (Araya et al., 2014; Yu et al., 2007). Regulation of Tbx21 by
Foxo1 seems to be important for controlling NK cell effector
functions and late-stage maturation, as our preliminary data
(data not shown) suggested that in murine NK cells, Foxo1
seems not to regulate other transcription factors known to
be required for NK cell development, such as Ikaros, Pu.1,
VDUP-1, E4BP4, Mef, Gata3, and Irf2.
Given the solid evidence that Tbx21 provides a positive deter-
ministic signal for late-stage NK cell maturation (Gordon et al.,
2012; Soderquest et al., 2011; Townsend et al., 2004), identifica-
tion of a new molecule acting as an upstream negative regulator
is of great significance. Our data support a notion that Tbx21 is a
downstream target of Foxo1, which we found negatively regu-
lates late-stage NK cell maturation and function. In addition to
the inverse expression between Foxo1 and Tbx21 in developing
andmature NK cells, twomore findings support this regulation of
Tbx21 by Foxo1. First, Tbx21 transcription and protein expres-
sion were found to be increased in NK cells with a specific deple-
tion of Foxo1, whereas overexpression of Foxo1 was found to
inhibit Tbx21 expression. Second, Foxo1 deficiency could not
rescue the late-stage maturation of NK cells in Tbx21/ mice;
however, Foxo1 deficiency promoted NK maturation when one
or both alleles of Tbx21 were present (Figures 7B and 7D).
Together, these results demonstrate that promotion of late-
stage NK cell maturation by reducing Foxo1 expression requires
Tbx21.
Dynamic changes in transcription factor regulation or expres-
sion might depend on extrinsic soluble factors secreted by other
cells, such as dendritic cells and/or monocytes, and external
stimuli. Thus, it would be intriguing to knowwhether the dynamic
changes occurring between Foxo1 and Tbx21 are regulated by
extrinsic factors and tumor challenges. In fact, we found that
stimulation of both NK-92 cells and murine NK cells with IL-15,
IL-2, and IL-12, even for a short time, led to Foxo1 phosphoryla-
tion. In vivo tumor challenges with B16F10 melanoma cells also
induce Foxo1 phosphorylation in mouse NK cells. Foxo1 phos-
phorylation has been shown to be associated with its cyto-
plasmic translocation, leading to reduced nuclear activity of
Foxo1, which might in turn evoke an increase in Tbx21 expres-
sion. Consistent with this, we and others have previously shown
that the above pro-inflammatory cytokines can upregulate
Tbx21 expression (Townsend et al., 2004; Yu et al., 2006).
In summary, we have demonstrated that in NK cells, Foxo
transcription factors regulate homing, late-stage maturation,
and effector functions. Mechanistically, we provide evidenceImmunity 42, 457–470, March 17, 2015 ª2015 Elsevier Inc. 465
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that Foxo1 inhibits Tbx21 expression through direct binding to
the Tbx21 promoter at a consensus forkhead-binding site in hu-
man NK cells, while through association with the promoter via
recruitment by Sp1 in murine NK cells. Our study indicates that
Foxo factors represent a novel negative regulatory element or
a checkpoint in NK cells, and provides a new avenue to target
NK cells for viral clearance and tumor surveillance based on
Foxo1 activity.
EXPERIMENTAL PROCEDURES
Mice
All mice were bred and housed in specific pathogen-free conditions in accor-
dance with Ohio State University Animal Care and Use Guidelines as well as
French and European Guidelines for Animal Care. All animal work was
approved by The Ohio State University Animal Care and Use Committee, as
well as Marseille’s Ethical Committee for Animal Use.
C57BL/6 Foxo1fl/fl and Foxo3fl/fl mice were a kind gift from Dr. Ming O. Li at
theMemorial Sloan-Kettering Cancer Center, as well as Dr. Ronald A. DePinho
at the Dana Farber Cancer Institute. Congenic C57BL/6 CD45.1 and Tbx21/
mice were purchased from The Jackson Laboratory. Congenic C57BL/6
Rag2/Il2rg/ mice were purchased from Taconic Biosciences. All mice
used were 8- to 12 weeks old.
Intravenous Lung Metastasis Assay
8- to 12-week-old Foxo1fl/fl (WT) or Ncr1iCre/+Foxo1fl/fl (Foxo1DNK) mice were
used for lung experimental-metastasis assays following intravenous injection
of 0.25 3 106 B16F10 melanoma cells. Two weeks after the injection, lung
tumor nodules were counted. To determine the amount of Foxo1 phosphory-
lation in NK cells in lung tissue, we challenged wild-type C57BL/6mice with i.v.
injections of 0.25 3 106 B16F10 melanoma cells for 7 days. Lung tissue
lymphocytes were isolated to detect the Foxo1 phosphorylation by flow
cytometry.
Immunoprecipitation Assay
Splenocytes were pooled from six mice, and 5 3 106 primary NK cells were
purified from the splenocytes by using a mouse NK negative selection kit
(Miltenyi Biotec), followed by FACS-sorting. Cell lysates were prepared using
a NP40 cell lysis buffer, supplemented with 10 mM phenylmethanesulfonyl
fluoride and 13 proteinase inhibitor cocktail (Sigma). An equal amount of
protein was used in each immunoprecipitation (IP), and was pre-cleared with
1 mg rabbit (for Foxo1 IP) or mouse (for Sp1 IP) immunoglobulin G (IgG) controlFigure 6. Foxo1 Inhibits Tbx21 Expression in Human NK Cells through D
by Sp1 to the Proximal Promoter Region
(A and B) Intracellular staining andmRNA content of Foxo1 (A) and Tbx21 (B) in CD
old WT C57BL/6 mice. The relative mean fluorescence intensity (MFI) and mRNA
CD11bCD27+ subset, is shown in the middle and right panels, respectively.
(C) Tbx21 protein expression assessed by intracellular staining of splenic NK ce
(D) Tbx21 mRNA expression in FACS-sorted splenic NK cells from WT or Foxo1
(E) Relative MFI of Tbx21 protein in CD11bCD27+, CD11b+CD27+, and CD11b+
(F) TBX21 transcript quantification by real-time RT-PCR in NKL cells expressing Fo
of IL-12.
(G) TBX21 transcript quantification by real-time RT-PCR in NKL cells expressing sh
for 12 hr.
(H) Schematic structure of the human TBX21 promoter with putative Foxo1 bindi
human NKL cells (bottom panel). The DNA precipitated by Foxo1 antibody was d
(I and J) Immunoblotting of endogenous Sp1 and Foxo1 in Foxo1 immunoprecip
murine NK cells (J).
(K) Recruitment of Foxo1 to themouse Tbx21 promoter region by Sp1. Chromatin
Sp1 antibody, or non-immune IgG. The precipitated DNA fragments were subjec
Tbx21 promoter region spanning from160 to +110 bp relative to the transcriptio
Data shown are representative of two (F, H, J, K) or three (C, D, E, G, I) independen
per group [C and D], n = 2 cultures per group [F and H], n = 3 cultures per group [Gantibodies plus 50 ml Dynabeads Protein A or Dynabeads Protein G, respec-
tively, for 2 hr at 4C. The precleaned lysates were then incubated with anti-
Foxo1 (C29H4) (1:100, Cell Signal Technology) or anti-Sp1 (E3) (5 mg, Santa
Cruz Technology) antibodies at 4C overnight. An equal volume of cell lysate,
incubated with the same species normal IgG, was taken as a control (Cell
Signaling Technology or Abcam). The immunoprecipitates were subsequently
incubated with 50 ml Dynabeads Protein A or Dynabeads Protein G for addi-
tional 4 hr at 4C, washed with lysis buffer, and subjected to immunoblotting
against Foxo1 (C29H4) (Cell Signaling Technology) or Sp1 (Millipore). A
Clean-Blot IP Detection Kit (HRP) (Pierce) was used as a secondary antibody.
ChIP Assay
ChIP assay was carried out using an EZ-ChIP assay kit (Upstate Biotech-
nology) as described previously (Deng et al., 2014). Briefly, an equal amount
(10 mg) of rabbit anti-Foxo1 (Abcam) antibody or normal rabbit IgG antibody
(Santa Cruz) was used to precipitate the cross-linked DNA/protein complexes
of 103 106 humanNKL cells. Similarly, an equal amount (7.5 mg) of anti-Foxo1,
anti-Sp1 antibody (Abcam), or normal rabbit IgG (Cell Signaling Technology)
was used to precipitate the cross-linked DNA/protein complexes from 5 3
106 mouse primary NK cells. Following reversal of cross-linking, the amount
of chromatin precipitated by the indicated antibody was detected by PCR.
The PCR primers were designed specially against the target regions and
were listed in the Supplemental Experimental Procedures online.
Flow Cytometric Analysis, In Vitro Assessment of NK Function,
Retroviral Transduction and Infection, and Quantitative
Real-Time RT-PCR
Standard protocols were followed for these procedures, which were pre-
sented in our previous publication (Yu et al., 2010) and were also detailed
in the Supplemental Experimental Procedures online.
Statistical Analysis
Unpaired Student’s t test was utilized to compare two independent groups
for continuous endpoints if they are normally distributed, or non-parametric
method (e.g., Wilcoxon Rank Sum test) was used if they are non-normally
distributed. One-way ANOVAwas performed when three or more independent
groups were compared and the assumptions of normality and equal variance
hold. Linear mixed models were used to account for the correlation due to the
repeated-measures from the same mouse. Generalized linear models were
used in the randomized block design with litters as the block factor. p values
were adjusted for multiple comparisons using Holm’s procedure. All tests
were two-sided. A p value less than 0.05 is considered statistically significant.
Data are presented as means ± SD.irect Promoter Binding and in Murine NK Cells through Recruitment
11bCD27+, CD11b+CD27+ and CD11b+CD27 splenic NK cells from 8-week-
of Foxo1 or Tbx21 in each NK cell subset, normalized to that detected in the
lls from WT or Foxo1DNK mice.
DNK mice measured by real-time RT-PCR.
CD27 splenic NK cells of WT and Foxo1DNK mice.
xo1-ER after addition of 4-OH-tamoxifen for the indicated time in the presence
RNA (shFoxo1) or the empty vector control (EV) following stimulationwith IL-12
ng sites (top panel) and ChIP assay of Foxo1 binding to the TBX21 promoter in
etected by PCR.
itates from murine splenocytes (I) or Foxo1 and Sp1 immunoprecipitates from
fromwild-typemurine NK cells was precipitated with anti-Foxo1 antibody, anti-
ted to PCR amplification using specific primers directed against the proximal
n start site. *p < 0.05, and **p < 0.01 (unpaired two-tailed Student’s t test, A–G).
t experiments. Error bars, SD (n = 4 to 6mice per group [A, B, E], n = 6 to 7mice
], and NK cells combined from six wild-type mice for one experiment [J and K]).
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Figure 7. Promotion of Late-Stage NK Cell Maturation by Loss of Foxo1 Requires Tbx21 Expression
(A and B) Analysis of CD11b versus CD27 expression in NK cells (gated on CD3NK1.1+ cells) in the bone marrow (BM), spleen, periphery lymph node (pLN),
and peripheral blood of 8-week-old Foxo1fl/fl (WT), Foxo1DNK, Foxo1DNK Tbx21/ and Tbx21/ (Tbx21 homozygotes, HO)mice (A) andWT, Foxo1DNK, Foxo1DNK
Tbx21+/, and Tbx21+/ (Tbx21 heterozygotes, HE) mice (B). Cell percentages of each NK cell developmental stage defined by CD11b and CD27 surface
expression are presented in the quadrants of dot plots, and the ratios (red) between CD27 versus CD27+ cells among CD11b+ NK cells are displayed at the right
side of each plot. Flow cytometry plots are representative of at least three independent experiments (nR 3 for each).
(C and D) Statistical analyses of the percentages of NK cells from each population defined by CD11b and CD27 expression in the spleens of themice described in
(A) and (B), respectively. NS, not significant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA, C and D). Error bars, SD (n = 6 to 7 for each genotype).
See also Figure S4.
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